✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Seizalam is a drug marketed by MMT and is included in one NDA.
The generic ingredient in SEIZALAM is midazolam hydrochloride. There are nine drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the midazolam hydrochloride profile page.
A generic version of SEIZALAM was approved as midazolam hydrochloride by FRESENIUS KABI USA on June 20th, 2000.
Recent Clinical Trials for SEIZALAM
Identify potential brand extensions & 505(b)(2) entrants
|Ology Bioservices||Phase 1|
|Joint Project Management Office for Chemical, Biological, Radiological, and Nuclear Medical||Phase 1|
|Rafa Laboratories||Phase 1|
Pharmacology for SEIZALAM
|Drug Class||Benzodiazepine |
SEIZALAM is protected by zero US patents and one FDA Regulatory Exclusivity.
FDA Regulatory Exclusivity protecting SEIZALAM
TREATMENT OF STATUS EPILEPTICUS IN ADULTS
Exclusivity Expiration: See Plans and Pricing
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Mmt||SEIZALAM||midazolam hydrochloride||SOLUTION;INTRAMUSCULAR||209566-001||Sep 14, 2018||RX||Yes||Yes||See Plans and Pricing||See Plans and Pricing||See Plans and Pricing|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|